Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Drugs in Development
Details:
Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Brodalumab,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Bausch Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 04, 2024
Lead Product(s) : Brodalumab,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Brodalumab in the Treatment of Immune-Related Adverse Events
Details : Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 04, 2024
Details:
KHK4827 is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Lead Product(s): Brodalumab,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Kyowa Kirin
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 03, 2020
Lead Product(s) : Brodalumab,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis
Details : KHK4827 is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 03, 2020
Details:
Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Lead Product(s): Brodalumab,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 01, 2020
Lead Product(s) : Brodalumab,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 01, 2020
Details:
KHK4827 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Scleroderma, Systemic.
Lead Product(s): Brodalumab,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2020
Lead Product(s) : Brodalumab,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of KHK4827 in Patients With Systemic Sclerosis
Details : KHK4827 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Scleroderma, Systemic.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 29, 2020
Details:
Secukinumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Lead Product(s): Secukinumab,Ixekizumab,Brodalumab,Guselkumab,Risankizumab,Tildrakizumab,Bimekizumab
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: ZonMw | Belgium Health Care Knowledge Centre | University Hospital Ghent
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 09, 2020
Lead Product(s) : Secukinumab,Ixekizumab,Brodalumab,Guselkumab,Risankizumab,Tildrakizumab,Bimekizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : ZonMw | Belgium Health Care Knowledge Centre | University Hospital Ghent
Deal Size : Inapplicable
Deal Type : Inapplicable
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
Details : Secukinumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 09, 2020
Details:
Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Lead Product(s): Brodalumab,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2020
Lead Product(s) : Brodalumab,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 12, 2020
Details:
Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Lead Product(s): Brodalumab,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2020
Lead Product(s) : Brodalumab,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 12, 2020
Details:
Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Lead Product(s): Brodalumab,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 03, 2019
Lead Product(s) : Brodalumab,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 4 Clinical Study of Brodalumab
Details : Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 03, 2019
Details:
KHK4827 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Lead Product(s): Brodalumab,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 19, 2019
Lead Product(s) : Brodalumab,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of KHK4827 in Subjects With Palmoplantar Pustulosis
Details : KHK4827 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 19, 2019
Details:
Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hidradenitis Suppurativa.
Lead Product(s): Brodalumab,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Bausch Health
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2019
Lead Product(s) : Brodalumab,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Bausch Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab
Details : Brodalumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hidradenitis Suppurativa.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 23, 2019
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
Company : Bausch Health U
Brodalumab
Drug Cost (USD) : 10,003,559
Year : 2023
Prescribers : 218
Prescriptions : 1865
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Bausch Health U
Brodalumab
Drug Cost (USD) : 9,014,594
Year : 2022
Prescribers : 224
Prescriptions : 1851
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Bausch Health U
Brodalumab
Drug Cost (USD) : 8,588,270
Year : 2021
Prescribers : 242
Prescriptions : 1981
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Valeant/Bausch
Brodalumab
Drug Cost (USD) : 9,379,407
Year : 2020
Prescribers : 301
Prescriptions : 2268
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Valeant/Bausch
Brodalumab
Drug Cost (USD) : 7,072,868
Year : 2019
Prescribers : 292
Prescriptions : 1785
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Valeant/Bausch
Brodalumab
Drug Cost (USD) : 3,135,421
Year : 2018
Prescribers : 169
Prescriptions : 754
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Annual Reports
Main Therapeutic Indication : Dermatology
Currency : USD
2020 Revenue in Millions : 27
2019 Revenue in Millions : 24
Growth (%) : 12
Main Therapeutic Indication : Dermatology
Currency : USD
2021 Revenue in Millions : 24
2020 Revenue in Millions : 27
Growth (%) : 4
Main Therapeutic Indication : Dermatology
Currency : USD
2022 Revenue in Millions : 23
2021 Revenue in Millions : 24
Growth (%) : -7
Main Therapeutic Indication : Dermatology
Currency : USD
2023 Revenue in Millions : 19
2022 Revenue in Millions : 23
Growth (%) : -7
Main Therapeutic Indication : Dermatology
Currency : USD
2024 Revenue in Millions : 18
2023 Revenue in Millions : 19
Growth (%) : -6
Main Therapeutic Indication : Dermatology
Currency : USD
2017 Revenue in Millions : 10
2016 Revenue in Millions : 1
Growth (%) : 900
Main Therapeutic Indication : Dermatology
Currency : USD
2018 Revenue in Millions : 13
2017 Revenue in Millions : 9
Growth (%) : 40%
Main Therapeutic Indication : Dermatology
Currency : USD
2019 Revenue in Millions : 23
2018 Revenue in Millions : 19
Growth (%) : 25
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patents & EXCLUSIVITIES
ABOUT THIS PAGE
